<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02709616</url>
  </required_header>
  <id_info>
    <org_study_id>Ag-mRNA-DC-999brain</org_study_id>
    <nct_id>NCT02709616</nct_id>
  </id_info>
  <brief_title>Personalized Cellular Vaccine for Glioblastoma (PERCELLVAC)</brief_title>
  <acronym>PERCELLVAC</acronym>
  <official_title>Personalized Cellular Vaccine Therapy in Treating Patients With Newly Diagnosed Glioblastoma (PerCellVac)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Guangdong 999 Brain Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Jinan University Guangzhou</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beijing Tricision Biotherapeutics Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Trinomab Biotech Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Guangdong 999 Brain Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dendritic cell-based cellular vaccine for tumor therapy has shown efficacy. This study is&#xD;
      designed to perform a personalized clinical trial by first analyzing the expression of tumor&#xD;
      associated antigens in patients with newly diagnosed glioblastoma and then immunizing the&#xD;
      patients with personalized DC-based cellular vaccine. Immune responses to tumor antigens will&#xD;
      be monitored. Safety and efficacy will be observed in the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open label, single-arm, single-institution, Phase I study designed to investigate&#xD;
      the safety and efficacy of personalized cellular tumor vaccine for patients with newly&#xD;
      diagnosed glioblastoma (GBM). Newly diagnosed GBM patients will undergo tumor resection. The&#xD;
      tumors will be analyzed for the expression of a panel of glioma-associated antigens and&#xD;
      immune-related genes. Post surgical treatment will be 6 weeks standard chemotherapy with&#xD;
      temozolomide and concurrent radiotherapy and continue cycles of temozolomide within a 28-day&#xD;
      window. Patients will undergo leukapheresis either after surgery or after concurrent&#xD;
      radio/chemotherapy. Based on individual tumor antigen expression, in vitro transcribed mRNA&#xD;
      will be generated and used to pulse in vitro generated DCs. The patients will be immunized&#xD;
      i.d. and i.v. biweekly with DC cellular vaccines. Safety and efficacy will be monitored. The&#xD;
      primary objective is to assess the safety of the personalized cellular vaccines. The&#xD;
      secondary objective is to assess the specific T cell response to immunized vaccines. In&#xD;
      addition, the antitumor efficacy of the vaccines will be measured using iRANO criteria,&#xD;
      progression-free survival and overall survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>March 2016</start_date>
  <completion_date type="Anticipated">June 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-emergent adverse events and severe adverse events [safety and Tolerability]</measure>
    <time_frame>3 years since the beginning of the first vaccine</time_frame>
    <description>Incidence of adverse events and severe adverse events to measure safety and tolerability of mRNA-TAA pulsed autologous DC cellular vaccine</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antitumor antigen specific T cell response</measure>
    <time_frame>4 weeks after the last vaccine</time_frame>
    <description>The frequency of peripheral CD8+ and CD4+ T cell response to the vaccine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>12 months since the beginning of the first vaccine.</time_frame>
    <description>Progression-free survival will be monitored for 1year.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3 years since the beginning of the first vaccine</time_frame>
    <description>Overall survival will be monitored for 3 years.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Glioblastoma</condition>
  <arm_group>
    <arm_group_label>Personalized cellular vaccine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DC based cellular vaccine</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Personalized cellular vaccine</intervention_name>
    <description>Biological: DC-based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive biweekly cellular vaccines.</description>
    <arm_group_label>Personalized cellular vaccine</arm_group_label>
    <other_name>Tumor antigen pulsed DC vaccine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Newly diagnosed glioblastoma grade IV&#xD;
&#xD;
          -  Patients at the age of 18-65.&#xD;
&#xD;
          -  Patients must have undergone maximal surgical resection of the tumor.&#xD;
&#xD;
          -  Patients with Karnofsky scores &gt; or =70&#xD;
&#xD;
          -  Patients with normal range of hematologic and metabolic test results.&#xD;
&#xD;
          -  Patients must have no corticosteroids treatment at least one week before vaccination.&#xD;
&#xD;
          -  Patients capable of understanding the study and signed informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Breast feeding females.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Infectious diseases HIV, HBV, HCV&#xD;
&#xD;
          -  Documented immunodeficiency&#xD;
&#xD;
          -  Documented autoimmune disease&#xD;
&#xD;
          -  Any serious or uncontrolled medical or psychiatric conditions, for example, severe&#xD;
             pulmonary, cardiac or other systemic disease.&#xD;
&#xD;
          -  Patient inability to participate as determined by PI discretion.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Zhang, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Guangdong 999 Brain Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Guangdong 999 Brain Hospital</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>March 7, 2016</study_first_submitted>
  <study_first_submitted_qc>March 10, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 16, 2016</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Guangdong 999 Brain Hospital</investigator_affiliation>
    <investigator_full_name>Jian Zhang</investigator_full_name>
    <investigator_title>Jian Zhang, MD, Professor, Vice President of Guangdong 999 Brain Hospital, Chairman, Department of Surgery</investigator_title>
  </responsible_party>
  <keyword>Glioblastoma</keyword>
  <keyword>DC vaccine</keyword>
  <keyword>tumor antigen</keyword>
  <keyword>personalized vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glioblastoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

